These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33761887)

  • 1. Beliefs about medication as predictors of medication adherence in a prospective cohort study among persons with multiple sclerosis.
    Neter E; Glass-Marmor L; Wolkowitz A; Lavi I; Miller A
    BMC Neurol; 2021 Mar; 21(1):136. PubMed ID: 33761887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication habits among persons with multiple sclerosis.
    Neter E; Glass-Marmor L; Wolkowitz A; Miller A
    Mult Scler Relat Disord; 2022 Dec; 68():104224. PubMed ID: 36242806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
    Lenz F; Harms L
    Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple modality approach to assess adherence to medications across time in Multiple Sclerosis.
    Neter E; Wolkowitz A; Glass-Marmor L; Lavi I; Ratzabi S; Leibkovitz I; Miller A
    Mult Scler Relat Disord; 2020 May; 40():101951. PubMed ID: 32004857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world persistence of multiple sclerosis disease-modifying therapies.
    Tallantyre EC; Dobson R; Froud JLJ; St John FA; Anderson VM; Arun T; Buckley L; Evangelou N; Ford HL; Galea I; George S; Gray OM; Hibbert AM; Hu M; Hughes SE; Ingram G; Kalra S; Lim CE; Mathews JTM; McDonnell GV; Mescall N; Norris S; Ramsay SJ; Rice CM; Russell MJ; Shawe-Taylor MJ; Williams TE; Harding KE; Robertson NP
    Eur J Neurol; 2024 Jul; 31(7):e16289. PubMed ID: 38567516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis.
    Zuckerman AD; DeClercq J; Simonson D; Zagel AL; Turco E; Banks A; Wawrzyniak J; Rightmier E; Blevins A; Choi L
    Mult Scler Relat Disord; 2023 Jul; 75():104738. PubMed ID: 37182475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study).
    Jongen PJ; Lemmens WA; Hoogervorst EL; Donders R
    Health Qual Life Outcomes; 2017 Mar; 15(1):50. PubMed ID: 28292329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication adherence to disease-modifying therapies among a cohort of Jordanian patients with relapsing-remitting multiple sclerosis: a multicentre cross-sectional study.
    Al-Keilani MS; Almomani BA
    Int J Pharm Pract; 2023 Apr; 31(2):198-205. PubMed ID: 36738264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to Disease-Modifying Therapies for Multiple Sclerosis.
    Higuera L; Carlin CS; Anderson S
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1394-1401. PubMed ID: 27882830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations Between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease-Modifying Therapies in Patients with Multiple Sclerosis.
    Thach AV; Brown CM; Herrera V; Sasane R; Barner JC; Ford KC; Lawson KA
    Int J MS Care; 2018; 20(6):251-259. PubMed ID: 30568562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis.
    Lafata JE; Cerghet M; Dobie E; Schultz L; Tunceli K; Reuther J; Elias S
    J Am Pharm Assoc (2003); 2008; 48(6):752-7. PubMed ID: 19019804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression.
    Mardan J; Hussain MA; Allan M; Grech LB
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1273-1295. PubMed ID: 34464209
    [No Abstract]   [Full Text] [Related]  

  • 14. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.
    Kleiter I; Lang M; Jeske J; Norenberg C; Stollfuß B; Schürks M
    BMC Neurol; 2017 Sep; 17(1):174. PubMed ID: 28877664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis.
    Li P; Ladage VP; Berger J; Chahin S; Jhaveri M; Geremakis C; Doshi JA
    Value Health; 2020 Mar; 23(3):328-334. PubMed ID: 32197728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication adherence and health outcomes in persons with multiple sclerosis treated with dimethyl fumarate.
    Jožef M; Locatelli I; Brecl Jakob G; Rot U; Kos M
    Mult Scler Relat Disord; 2023 Apr; 72():104615. PubMed ID: 36933300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized Intervention to Improve Medication Adherence for Persons with Multiple Sclerosis.
    Neter E; Esterkin-Hubner E; Glass-Marmor L; Wolkowitz A; Lavi I; Miller A
    Patient Prefer Adherence; 2024; 18():1195-1203. PubMed ID: 38895639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.
    Col NF; Solomon AJ; Alvarez E; Pbert L; Ionete C; BerriosMorales I; Chester J; Kutz C; Iwuchukwu C; Livingston T; Springmann V; Col HV; Ngo LH
    Mult Scler Relat Disord; 2023 Dec; 80():105092. PubMed ID: 37931489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
    Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
    J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.